Zilxi (Minocycline HCl) Patent Expiration, LOE Window & CMS Spending

Zilxi (Minocycline HCl) by Journey Medical: FDA Orange Book LOE 2030-10-01, 16 AB generics, $430K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJourney Medical
FDA Application & PathwayN213690 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-10-01
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors16
2024 CMS Total Public Spend$430K
2024 Medicare Part D Spend$430K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel